This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
Tandem Diabetes' (TNDM) Insulin Pump Approved by Health Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology cleared for use in Canada post the receipt of Health Canada approval.
Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
Zacks.com featured highlights include: The New York Times, Apple and Tandem Diabetes Care
by Zacks Equity Research
Zacks.com featured highlights include: The New York Times, Apple and Tandem Diabetes Care
3 Stocks to Watch Closely for Superb Earnings Acceleration
by Tirthankar Chakraborty
At present, the New York Times (NYT), Apple (AAPL) and Tandem Diabetes Care (TNDM) are some of the few companies boasting solid earnings acceleration.
Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.
Insulet (PODD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.
3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic
by Debanjana Dey
Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.
Tandem Diabetes' Advanced Insulin Pump Study Results Favorable
by Zacks Equity Research
Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.
Medtronic Plans New Acquisition in AI-Driven Diabetes Care
by Zacks Equity Research
Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend
by Sriparna Ghosal
Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Abbott, Tandem Diabetes Seal Deal on Diabetes Management
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.
Tandem Diabetes' Sugarmate Buyout Boosts Digital Offerings
by Zacks Equity Research
Tandem Diabetes (TNDM) expands digital portfolio with the Sugarmate app buyout, paving the way for the company's expansion of diabetes-related products and services ecosystem.
Tandem Diabetes Gets Expanded Indication for Insulin Pump
by Zacks Equity Research
Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.
Tandem Diabetes (TNDM) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Tandem Diabetes (TNDM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments
Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis
by Zacks Equity Research
Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).
Here's Why You Should Hold on to Tandem Diabetes Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.
Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
Here's Why You Should Add Tandem Diabetes to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.
Buy These 5 Low Leverage Stocks Amid Coronavirus-Led Sell Off
by Zacks Equity Research
This is a good time to go for safe stocks so that in the event of any further market turmoil the stockholders do not lose significantly. Stocks with low debt-to-equity ratio offer that safety.